Literature DB >> 33947421

Impact of mixed meal tolerance test composition on measures of beta-cell function in type 2 diabetes.

Theresa Kössler1,2,3, Pavel Bobrov3,4, Klaus Strassburger3,4, Oliver Kuss3,4, Oana-Patricia Zaharia1,2,3, Yanislava Karusheva2,3, Clara Möser2,3, Kálmán Bódis1,2,3, Volker Burkart2,3, Michael Roden1,2,3, Julia Szendroedi5,6,7,8.   

Abstract

BACKGROUND: Application of mixed meal tolerance tests (MMTT) to measure beta-cell function in long-term studies is limited by modification of the commercial products occurring over time. This study assessed the intra-individual reliability of MMTTs and compared the effects of liquid meals differing in macronutrient composition on the estimation of beta-cell function in type 2 diabetes (T2DM).
METHODS: To test the reliability of MMTTs, 10 people with T2DM (age 58 ± 11 years, body mass index 30.0 ± 4.9 kg/m2) received Boost® high Protein 20 g protein three times. For comparing different meals, another 10 persons with T2DM (58 ± 5 years, 31.9 ± 5.3 kg/m2) ingested either Boost® high Protein 20 g protein or the isocaloric Boost® high Protein 15 g protein containing 35% less protein and 18% more carbohydrates. C-peptide, insulin and glucose release were assessed from the incremental area under the concentration time curve (iAUC) and the intra- and inter-individual variation of these parameters from the coefficients of variations (CV).
RESULTS: Repetitive ingestion of one meal revealed intra-individual CVs for the iAUCs of C-peptide, insulin and glucose, which were at least 3-times lower than the inter-individual variation of these parameters (18.2%, 19.7% and 18.9% vs. 74.2%, 70.5% and 207.7%) indicating a good reliability. Ingestion of two different meals resulted in comparable intra-individual CVs of the iAUCs of C-peptide and insulin (16.9%, 20.5%).
CONCLUSION: MMTTs provide reliable estimation of beta-cell function in people with T2DM. Furthermore, moderate differences in the protein and carbohydrate contents in a standardized liquid meal do not result in relevant changes of C-peptide and insulin responses. TRIAL REGISTRATION: Clinicaltrials.gov, Identifier number: NCT01055093. Registered 22 January 2010 - Retrospectively registered, https://www.clinicaltrials.gov/ct2/show/study/NCT01055093.

Entities:  

Keywords:  Beta-cell function; Inter-individual variation; Intra-individual variation; Mixed meal tolerance test; Type 2 diabetes

Year:  2021        PMID: 33947421     DOI: 10.1186/s12986-021-00556-1

Source DB:  PubMed          Journal:  Nutr Metab (Lond)        ISSN: 1743-7075            Impact factor:   4.169


  15 in total

1.  Postprandial metabolic responses to mixed versus liquid meal tests in healthy men and men with type 2 diabetes.

Authors:  Kimberly G Brodovicz; Cynthia J Girman; Annemarie M C Simonis-Bik; Josina M Rijkelijkhuizen; Maartje Zelis; Mathijs C Bunck; Andrea Mari; Giel Nijpels; E Marelise W Eekhoff; Jacqueline M Dekker
Journal:  Diabetes Res Clin Pract       Date:  2011-09-28       Impact factor: 5.602

2.  Another approach to estimating the reliability of glycaemic index.

Authors:  Sheila M Williams; Bernard J Venn; Tracy Perry; Rachel Brown; Alison Wallace; Jim I Mann; Tim J Green
Journal:  Br J Nutr       Date:  2008-01-11       Impact factor: 3.718

3.  Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series.

Authors:  Sudha S Shankar; Adrian Vella; Ralph H Raymond; Myrlene A Staten; Roberto A Calle; Richard N Bergman; Charlie Cao; Danny Chen; Claudio Cobelli; Chiara Dalla Man; Mark Deeg; Jennifer Q Dong; Douglas S Lee; David Polidori; R Paul Robertson; Hartmut Ruetten; Darko Stefanovski; Maria T Vassileva; Gordon C Weir; David A Fryburg
Journal:  Diabetes Care       Date:  2016-07-12       Impact factor: 19.112

4.  Plasma glucose and insulin profiles in normal subjects ingesting diets of varying carbohydrate, fat, and protein content.

Authors:  F Q Nuttall; M C Gannon; J L Wald; M Ahmed
Journal:  J Am Coll Nutr       Date:  1985       Impact factor: 3.169

5.  Meal-derived glucagon responses are related to lower hepatic phosphate concentrations in obesity and type 2 diabetes.

Authors:  K S Weber; K Straßburger; M Fritsch; A Bierwagen; C Koliaki; E Phielix; G Pacini; J-H Hwang; D F Markgraf; V Burkart; K Müssig; J Szendroedi; M Roden
Journal:  Diabetes Metab       Date:  2018-06-02       Impact factor: 6.041

6.  Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort.

Authors:  Josina M Rijkelijkhuizen; Cynthia J Girman; Andrea Mari; Marjan Alssema; Thomas Rhodes; Giel Nijpels; Piet J Kostense; Peter P Stein; Elisabeth M Eekhoff; Robert J Heine; Jacqueline M Dekker
Journal:  Diabetes Res Clin Pract       Date:  2008-12-20       Impact factor: 5.602

Review 7.  Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives.

Authors:  B Ahrén
Journal:  Diabetes Metab       Date:  2013-05-02       Impact factor: 6.041

8.  Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.

Authors:  Carla J Greenbaum; Thomas Mandrup-Poulsen; Paula Friedenberg McGee; Tadej Battelino; Burkhard Haastert; Johnny Ludvigsson; Paolo Pozzilli; John M Lachin; Hubert Kolb
Journal:  Diabetes Care       Date:  2008-07-15       Impact factor: 19.112

9.  Adding to the spectrum of insulin sensitive populations for mixed meal tolerance test glucose reliability assessment.

Authors:  Sabina Paglialunga; Angelica Guerrero; Julie M Roessig; Paul Rubin; Clayton A Dehn
Journal:  J Diabetes Metab Disord       Date:  2016-12-07

10.  Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes.

Authors:  Rachel E J Besser; Beverley M Shields; Rosaura Casas; Andrew T Hattersley; Johnny Ludvigsson
Journal:  Diabetes Care       Date:  2012-10-30       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.